Pipeline-focused public companies
Find biotechnology and pharmaceutical companies by market profile and drug-development maturity, then open each ticker for its stock, pipeline and catalyst research page.
| Company | Price | Market cap | Pipeline | Next catalyst | Open |
|---|---|---|---|---|---|
| IN INVAInnoviva | $21.07+0.3% | $1.52B | 5 assetsApproved | No dated catalyst | |
| IN INZYInozyme Pharma | $4.00+0.0% | $258.2M | 4 assetsStage unavailable | No dated catalyst | |
| IO IOBTIO Biotech | $0.05+0.0% | $3.5M |
The screener is the parent research index for individual ticker pages such as CAPR. Filter the biotech company universe here, then open a company to review its stock snapshot, drug assets, clinical stage and dated catalysts. Quote information is a cached market snapshot and may be delayed.
2 assetsStage unavailable |
| No dated catalyst |
| IO IONSIonis Pharmaceuticals | $59.74+1.7% | $9.93B | 25 assetsApproved | Eplontersen (AKCEA-TTR-LRx) Phase 3 · Data readout |
| IO IOVAIovance Biotherapeutics | $8.29-7.8% | $3.76B | 14 assetsPhase 2 | Amtagvi/Lifileucel (LN-144) (TIL Therapy)Phase 2 · Data readout |
| IP IPHAInnate Pharma SA | $2.26+8.1% | $252.4M | 15 assetsPhase 3 | Monalizumab + durvalumab + oleclumabPhase 3 · Data readout |
| IP IPSCCentury Therapeutics | $2.07+2.5% | $374.8M | 5 assetsPhase 1/2 | CNTY-101Phase 1/2 · Data readout |
| IP IPSEYIpsen | $47.60+0.0% | $15.73B | 16 assetsPhase 3 | IPN10200Phase 2 · Data readout |
| IR IRONDisc Medicine Inc | $79.81+1.2% | $3.06B | 9 assetsPhase 3 | DISC-3405 (formerly MWTX-003)Phase 2 · Data readout |
| IR IRWD Ironwood Pharmaceuticals | $4.29+3.6% | $708.9M | 9 assetsStage unavailable | No dated catalyst |
| IS ISEEIVERIC bio | $39.95+0.0% | — | 2 assetsStage unavailable | No dated catalyst |
| IT ITCIIntra-Cellular Therapies | $131.87+0.0% | — | 13 assetsStage unavailable | No dated catalyst |
| IT ITOSiTeos Therapeutics | $10.15+0.0% | $448.7M | 5 assetsStage unavailable | No dated catalyst |
| IT ITRMIterum Therapeutics | $0.03+0.0% | $1.6M | 3 assetsStage unavailable | No dated catalyst |
| IV IVA Inventiva | $4.68+0.6% | $1.11B | 4 assetsPhase 3 | Lanifibranor (Pan-PPAR)Phase 3 · Data readout |
| IV IVVDINVIVYD | $1.00+4.8% | $293.7M | 4 assetsPhase 3 | VYD2311Phase 3 · Data readout |
| IX IXHLIncannex Healthcare | $3.57-1.4% | $42.7M | 2 assetsStage unavailable | No dated catalyst |
| JA JAGXJaguar Health | $0.87-0.7% | $4.3M | 3 assetsStage unavailable | No dated catalyst |
| JA JANXJanux Therapeutics | $17.39+0.6% | $1.06B | 5 assetsPhase 1b | JANX011 (CD19 Bispecific)Phase 1 · Data readout |
| JA JAZZJazz Pharmaceuticals | $254.28+2.2% | $16.51B | 31 assetsPDUFA | Ziihera® (zanidatamab-hrii) + chemoPDUFA · Approval decision |
| JB JBIOJade Biosciences | $21.34+0.5% | $1.36B | 3 assetsPhase 1 | JADE201Phase 1 · Data readout |
| JN JNJJohnson & Johnson | $270.24+1.1% | $651.25B | 62 assetsStage unavailable | No dated catalyst |
| JS JSPRJasper Therapeutics | $0.72+3.6% | $23.8M | 6 assetsPhase 2 | Vensobafusp Alfa (KP-104) (Dual Complement Inhibitor)Phase 2 · Data readout |
| JU JUNSJupiter Neurosciences | $6.20+19.9% | $4.8M | 1 assetsPhase 2a | JOTROL (Resveratrol)Phase 2a · Data readout |
| KA KAKineta | $0.57 | — | 2 assetsStage unavailable | No dated catalyst |
| KA KALAKala Pharmaceuticals | $0.82-2.4% | $1.5M | 3 assetsStage unavailable | No dated catalyst |
| KA KALVKalvista Pharmaceuticals | $27.00+0.0% | $1.44B | 4 assetsStage unavailable | No dated catalyst |
| KA KANTKineta | $0.34+0.0% | $4.6M | 1 assetsStage unavailable | No dated catalyst |
| KA KAPAKairos Pharma | $0.29-1.7% | $6.9M | 2 assetsStage unavailable | No dated catalyst |
| KA KARDKardigan™ | $21.02+3.8% | $1.97B | 3 assetsPhase 2b | TonlamarsenPhase 2 · Data readout |
| KD KDMNKadmon Corporation | $9.50+0.0% | — | 1 assetsStage unavailable | No dated catalyst |
| KL KLDOKaleido Biosciences | $0.00+0.0% | $4,262 | 3 assetsStage unavailable | No dated catalyst |
| KL KLRAKailera Therapeutics | $17.17-1.7% | $2.23B | 4 assetsPhase 2b | KAI-7535 (GLP-1 Agonist)Phase 2 · Data readout |
| KL KLRSKalaris Therapeutics | $4.15+0.7% | $98.8M | 1 assetsPhase 1/2 | TH103Phase 1/2 · Data readout |
| KM KMDAKamada | $8.24+2.7% | $475.4M | 3 assetsStage unavailable | No dated catalyst |
| KN KNSAKiniksa Pharmaceuticals | $79.03+0.7% | $6.17B | 8 assetsPhase 3 | No dated catalyst |
| KN KNTEKinnate Biopharma | $2.65+0.0% | — | 3 assetsStage unavailable | No dated catalyst |
| KO KODKodiak Sciences Inc. | $38.33-3.8% | $2.41B | 8 assetsBLA | KSI-501 (anti-VEGF & IL-6)Phase 3 · Data readout |
| KP KPTIKaryopharm Therapeutics | $1.96+7.7% | $44.5M | 12 assetsPhase 3 | XPOVIO (Selinexor)Phase 2 · Data readout |
| KR KRONKronos Bio | $0.88+1.5% | $53.7M | 4 assetsStage unavailable | No dated catalyst |